抗体依赖性增强作用及对新型冠状病毒疫苗研发的思考

doi:10.19803/j.1672-8629.2021.03.01

摘要/Abstract

摘要： 通常情况下病毒性疫苗诱导机体产生的中和抗体能与入侵病毒结合并使其失去感染宿主细胞和发生疾病的能力,但在某些情况下疫苗接种后诱导产生的抗体不但未产生保护作用,反而加重了疾病的临床表现,即通过抗体依赖性增强作用导致疫苗增强性疾病。本文对既往疫苗临床研究和冠状病毒动物试验研究中发生的抗体依赖性增强作用及其可能的作用机制等进行了综述和分析,提出了对新型冠状病毒疫苗研发过程中安全性的思考,为尽早发现和认知抗体依赖性增强作用/疫苗增强性疾病并进行风险控制提供参考。

关键词: 抗体依赖性增强作用, 新型冠状病毒, 疫苗, 安全性, 风险控制

Abstract: Generally, the neutralizing antibodies may bind specifically to the invading virus particles, and prevent the virus from entering host cells and developing diseases. However, in some cases, these antibodies not only fail to function well, but also aggravate the clinical manifestations of the disease, known as antibody-dependent enhancement (ADE) that leads to vaccine-enhanced disease(VED). In this article, we investigated and analyzed cases of ADE that had occurred in previous clinical studies or during animal experiments related coronavirus vaccines, and the potential function mechanisms of ADE, and reflected on safety issues concerning the development of coronavirus vaccines, so as to provide reference for the early detection and recognition of ADE and risk control.

Key words: antibody-dependent enhancement, SARS-CoV-2, vaccine, safety, risk control

中图分类号:

R954.5

邓霞, 刘波, 王远征, 殷霄, 苏瑶, 张雁, 李英丽, 高晨燕, 杨焕, 王涛. 抗体依赖性增强作用及对新型冠状病毒疫苗研发的思考[J]. 中国药物警戒, 2021, 18(3): 201-205.

DENG Xia, LIU Bo, WANG Yuanzheng, YIN Xiao, SU Yao, ZHANG Yan, LI Yingli, GAO Chenyan, YANG Huan, WANG Tao. Antibody-Dependent Enhancement of Vaccines and Development of Coronavirus Vaccines[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 201-205.

参考文献

[1] WHO. Draft landscape of COVID-19 candidate vaccines 9 September2020[EB/OL].[2020-09-22]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[2] Hawkes RA.Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls[J]. Aust J Exp Biol Med Sc, 1964, 42(4): 465-482.
[3] Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody[J]. The Journal of Experimental Medicine, 1977, 146(1): 201-217.
[4] Halstead SB.Dengue haemorrhagic fever-a public health problem and a field for research[J]. Bull World Health Organ, 1980, 58(1): 1-21.
[5] Sangkawibha N, Rojanasuphot S, Ahandrik S, et al.Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand: I. the 1980 outbreak[J]. Am J Epidemiol, 1984, 120(5): 653-669.
[6] Huisman W, Martina BE, Rimmelzwaan GF, et al.Vaccine-induced enhancement of viral infections[J]. Vaccine, 2009, 27(4): 505-512.
[7] Takada A, Watanabe S, Okazaki K, et al.Infectivity-enhancing antib-odies to Ebola virus glycoprotein[J]. Virol, 2001, 75(5): 2324-2330.
[8] Takada A, Feldmann H, Thomas G, et al.Antibody-dependent enhancement of Ebola virus infection[J]. Virol, 2003, 77(13): 7539-7544.
[9] Wan YS, Shang J,Sun SH, et al.Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J]. Virol, 2020 (5): 94.
[10] Lambert PH, Ambrosino DM, Andersen SR, et al.Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines[J]. Vaccine, 2020, 38(31): 4783-4791.
[11] Hadinegoro SR, Arredondo-García JL, Capeding MR, et al.Efficacy and long-term safety of a dengue vaccine in regions of endemic disease[J]. N Engl J Med, 2015, 373(13): 1195-1206.
[12] Katzelnick LC, Gresh L, Halloran ME, et al.Antibody-dependent enhancement of severe dengue disease in humans[J]. Science, 2017, 358(6365): 929-932.
[13] Wang TT, Sewatanon J, Memoli MJ, et al.IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity[J]. Science, 2017, 355(6323): 395-398.
[14] Chin J, Magoffin RL, Shearer LA, et al.Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population[J]. Am J Epidemiol, 1969, 89(4): 449-463.
[15] Openshaw PJ, Tregoning JS.Immune responses and disease enhancement during respiratory syncytial virus infection[J].Clinical Microbiology Reviews, 2005, 18(3): 541-555.
[16] Vaccines(疫苗学). Sixth Edition[M] Page 1763, Chapter 55-Respi-ratory syncytial virus and parainfluenza virus vaccines, People's Medical Publishing House.
[17] Rauh LW, Schmidt R.Measles immunization with killed virus vaccine. serum antibody titers and experience with exposure to measles epidemic. 1965[J]. Bull World Health Organ, 2000, 78(2): 226-231.
[18] Philip MD, Nader R, Marshall , et al. Atypical exanthem following exposure to natural measles: Eleven cases in children previously inoculated with killed vaccine[J]. The Journal of Pediatrics, 1968, 72(1): 22-28.
[19] Polack FP, Hoffman SJ, Crujeiras G, et al.A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles[J]. Nat Med, 2003, 9(9): 1209-1213.
[20] Lin JT, Zhang JS, Su N, et al.Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine[J]. Antivir Ther, 2007, 12(7): 1107-1113.
[21] Martina JE, Louder MK.A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial[J]. Vaccine, 2008, 26: 6338-6343.
[22] Modjarrad K, Roberts CC, Mills KT, et al.Safety and immu- nogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1,open-label, single-arm, dose-escalation trial[J]. Lancet Infect Dis, 2019, 19(9): 1013-1102.
[23] Arvin AM, Fink K, Schmid MA, et al.A perspective on potential antibody-dependent enhancement of SARS-CoV-2[J]. Nature, 2020, 584: 353-363.
[24] Weiss RC, Scott FW.Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever[J]. Comp Immunol Microbiol Infect Dis, 1981, 4(2): 175-189.
[25] Vennema H, Groot de RJ, Harbour DA, et al. Early death after feline Infectious peritonitis virus challenge due to recombinant vaccinia virus immunization[J]. Virol, 1990, 64(3): 1407-1409.
[26] Liu L, Wei Q, Lin Q, et al.Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection[J]. JCI Insight, 2019, 4(4): 123158.
[27] Yip MS, Leung NHL, Cheung CY, et al.Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus[J]. Virol, 2014,11:82.
[28] Wang QD, Zhang LF, Kuwahara K, et al.Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates[J]. ACS Infect Dis, 2016 , 2(5): 361-376.
[29] Tseng CT, Sbrana E, Yoshikawa NI, et al.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J]. PLoS One, 2012, 7(4): e35421.
[30] Yasui F, Kai C, Kitabatake M, et al.Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV[J]. Immunol, 2008, 181(9): 6337-6348.
[31] Agrawal AS, Tao X, Algaissi A, et al.Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus[J]. Hum Vaccin Immunother, 2016, 12(9): 2351-2356.
[32] Yin Huajing, Wang Yin,Wu Shuang, et al.Considerations on the evaluation of non-clinical study on the SARS-CoV-2 vaccine[J]. Chinese Journal of Biologicals(中国生物制品学杂志), 2020, 33(4): 486-488.